Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute promyelocytic leukemia

R P Warrell1, H de Thé, Z Y Wang

  • 1Department of Medicine, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York 10021.

The New England Journal of Medicine
|July 15, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: The tumor suppressor protein PML controls apoptosis induced by the HIV-1 envelope.

Cell death and differentiation·2026
Same author

[Confronted to medical error, emphasize its positive aspects].

La Revue de medecine interne·2014
Same author

Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients.

Leukemia·2014
Same author

Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen.

British journal of cancer·2014
Same author

Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL.

Leukemia·2012
Same author

(+)α-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivo.

Leukemia·2011

Differentiation therapy, using agents like all-trans-retinoic acid, offers a practical approach to treating human cancers. Combining these differentiation agents shows promise for future cancer treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Differentiation therapy has emerged as a significant advancement in cancer treatment.
  • All-trans-retinoic acid (ATRA) demonstrated effectiveness in acute promyelocytic leukemia (APL).
  • ATRA possesses undesirable pharmacologic properties, prompting research into alternative retinoids like 9-cis-retinoic acid.

Purpose of the Study:

  • To highlight the significance of differentiation as a cancer treatment modality.
  • To explore alternative retinoids and other agents with cytodifferentiating actions.
  • To discuss the potential of combination therapies involving differentiation agents.

Main Methods:

  • Review of existing literature on differentiation agents and their mechanisms.

Related Experiment Videos

  • In vitro studies on the activity of retinoids and other compounds against cancer cells.
  • Analysis of the therapeutic potential of combining differentiation agents with conventional treatments.

    • Main Results:

    • All-trans-retinoic acid (ATRA) effectively treats acute promyelocytic leukemia by inducing cell differentiation.
    • Alternative retinoids (e.g., 9-cis-retinoic acid) and other compounds (e.g., vitamin D3, sodium butyrate) also exhibit cytodifferentiating actions.
    • Combination therapies involving differentiation agents show amplified activity and promise for novel oncologic approaches.

    Conclusions:

    • Differentiation therapy is a validated and practical method for treating human cancers.
    • The insights gained from acute promyelocytic leukemia serve as a model for broader cancer therapy applications.
    • Combination differentiation agents represent a promising next-generation approach for cancer treatment.